Icon to close the modal
Support
Sales
Phone Icon
1.844.8.BD.LIFE (1.844.823.5433)
Modal Close Icon
Sales Form
Please fill out the form and a sales representative will get in touch with you.

Capability:

Product Line:

Icon to close thank you modal
Thank you for contacting our sales team!
A sales representive will get in touch with you shortly.
Ordering
Phone Icon
1.844.8.BD.LIFE (1.844.823.5433)
Onsite Visiting
Location Icon
850 W Rio Salado Pkwy, Tempe, AZ 85281 United States
Customer Service
Phone Icon
1.844.8.BD.LIFE (1.844.823.5433)
6:00 a.m. – 4:30 p.m. Arizona Time (Monday-Friday)
Fax Icon
1.800.440.5376
LifeStent™ Solo™ Vascular Stent System

FDA-approved for the SFA and full popliteal artery

Contact Us navigation arrow
Carousel Image
Loading
tabs dropdown arrow
Overview

The LifeStent™ Solo™ Vascular Stent is the first commercially available 200 mm stent in the U.S. and potentially enables a single-stent solution. The LifeStent™ Solo™ Vascular Stent has sustained effectiveness up to three years in longer lesions. Furthermore, its enhanced delivery system is designed to reduce delivery system-dependent stent compression or elongation and enhance deployment accuracy. The LifeStent™ Vascular Stent Systems, in varying sizes, have been studied in more than ten clinical trials in the United States and globally.

The LifeStent™ Solo™ Vascular Stent is a peripheral stent intended to improve luminal diameter in the treatment of symptomatic de-novo or restenotic lesions up to 240mm in length in the native superficial femoral artery (SFA) and popliteal artery with reference vessel diameters ranging from 4.0 – 6.5mm. The LifeStent™ Vascular Stent is the only FDA-approved stent for the SFA and full popliteal artery. The LifeStent™ Solo™ Vascular Stent is available in 6 mm and 7 mm diameters and 200 mm in length.

Additionally, the LifeStent™ Vascular Stent is available in 5 mm, 6 mm, and 7 mm diameters; and 20 mm to 170 mm in length.

true
Features and Benefits
Longest lesion length indication (up to 240 mm)1
Proven performance in long lesions2
Designed for enhanced distal and proximal stent placement accuracy
Treat longer lesions with one stent

About LifeStent™ Solo™ Vascular Stent

The LifeStent™ Solo™ Vascular Stent is the first commercially available 200 mm stent in the U.S. and potentially enables a single-stent solution. The LifeStent™ Solo™ Vascular Stent has sustained effectiveness up to three years in longer lesions. Furthermore, its enhanced delivery system is designed to reduce delivery system-dependent stent compression or elongation and enhance deployment accuracy. The LifeStent™ Vascular Stent Systems, in varying sizes, have been studied in more than ten clinical trials in the United States and globally.

The LifeStent™ Solo™ Vascular Stent is a peripheral stent intended to improve luminal diameter in the treatment of symptomatic de-novo or restenotic lesions up to 240mm in length in the native superficial femoral artery (SFA) and popliteal artery with reference vessel diameters ranging from 4.0 – 6.5mm. The LifeStent™ Vascular Stent is the only FDA-approved stent for the SFA and full popliteal artery. The LifeStent™ Solo™ Vascular Stent is available in 6 mm and 7 mm diameters and 200 mm in length.

Additionally, the LifeStent™ Vascular Stent is available in 5 mm, 6 mm, and 7 mm diameters; and 20 mm to 170 mm in length. To learn more about the LifeStent™ Vascular Stent, please click here

Reference

1. As of December 2020

2. LifeStent™ Solo™ Vascular Stent Delivery System Study. A single-arm, prospective, non-randomized, multi-center study evaluating the safety and effectiveness of the LifeStent™ Solo™ in the treatment of symptomatic vascular disease of the SFA and/or proximal popliteal artery. Subjects were treated with conventional PTA followed by implantation of the LifeStent™ Vascular Stent. The LifeStent™ 5 mm diameter was not included in this trial.

3. RESILIENT I Trial, RESILIENT II Trial, E-TAGIUSS Trial, Retrospective Analysis of LifeStent® Vascular Stent Systems in the Treatment of Long-Segment Lesions, LifeStent® Vascular Stent Delivery System Study (LifeStent® 200 mm Trial),REALITY I Trial,REALITY II Trial, ETAP Trial, CONTINUUM Trial, and RELIABLE Trial. Additional trials ongoing.

Please consult Instructions for Use for product indications for use, contraindications, warnings, precautions, complications, adverse events and detailed safety information.

true

BD-23531

Products & Accessories
  • product-image

    LifeStent™ Solo™ Vascular Stent, 7 mm x 200 mm, on a 100 cm, 6 French Catheter.

  • product-image

    LifeStent™ Solo™ Vascular Stent, 6 mm x 200 mm, on a 135 cm, 6 French Catheter.

  • product-image

    LifeStent™ Solo™ Vascular Stent, 7 mm x 200 mm, on a 135 cm, 6 French Catheter.

  • product-image

    LifeStent™ Solo™ Vascular Stent, 6 mm x 200 mm, on a 100 cm, 6 French Catheter.

References

1. As of December 2020

2. LifeStent™ Solo™ Vascular Stent Delivery System Study. A single-arm, prospective, non-randomized, multi-center study evaluating the safety and effectiveness of the LifeStent™ Solo™ in the treatment of symptomatic vascular disease of the SFA and/or proximal popliteal artery. Subjects were treated with conventional PTA followed by implantation of the LifeStent™ Vascular Stent. The LifeStent™ 5 mm diameter was not included in this trial.

3. RESILIENT I Trial, RESILIENT II Trial, E-TAGIUSS Trial, Retrospective Analysis of LifeStent® Vascular Stent Systems in the Treatment of Long-Segment Lesions, LifeStent® Vascular Stent Delivery System Study (LifeStent® 200 mm Trial),REALITY I Trial,REALITY II Trial, ETAP Trial, CONTINUUM Trial, and RELIABLE Trial. Additional trials ongoing.

Please consult Instructions for Use for product indications for use, contraindications, warnings, precautions, complications, adverse events and detailed safety information.

true

BD-23531

Resources
References

1. As of December 2020

2. LifeStent™ Solo™ Vascular Stent Delivery System Study. A single-arm, prospective, non-randomized, multi-center study evaluating the safety and effectiveness of the LifeStent™ Solo™ in the treatment of symptomatic vascular disease of the SFA and/or proximal popliteal artery. Subjects were treated with conventional PTA followed by implantation of the LifeStent™ Vascular Stent. The LifeStent™ 5 mm diameter was not included in this trial.

3. RESILIENT I Trial, RESILIENT II Trial, E-TAGIUSS Trial, Retrospective Analysis of LifeStent® Vascular Stent Systems in the Treatment of Long-Segment Lesions, LifeStent® Vascular Stent Delivery System Study (LifeStent® 200 mm Trial),REALITY I Trial,REALITY II Trial, ETAP Trial, CONTINUUM Trial, and RELIABLE Trial. Additional trials ongoing.

Please consult Instructions for Use for product indications for use, contraindications, warnings, precautions, complications, adverse events and detailed safety information.

true

BD-23531

Chat with us
Our live chat is available between the hours of 8.30am - 5.00pm EST, Monday - Friday
×